CERS - シ―ラス (Cerus Corporation) シ―ラス

 CERSのチャート


 CERSの企業情報

symbol CERS
会社名 Cerus Corp. (シ―ラス)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 シーラス(Cerus Corporation)は生物医学製品会社であり、血液の安全性を高めるために自社の「インターセプト・ブラッド・システム(INTERCEPT Blood System)」の商業化を中心に事業を展開する。同社は、血液安全セグメントを通じて事業を行う。同社のINTERCEPT血液システムは、生物学的複製を制御する技術に基づいて、輸血を目的とする寄贈血液成分中の血液媒介病原体を減少させるように設計される。同社のINTERCEPT血液システムは、ヒト免疫不全ウイルス(HIV)、西ナイル病、重症急性呼吸器症候群(SARS)、B型肝炎・C型肝炎、細菌や寄生虫を含むウイルスなどの血液媒介病原体を標的とし、それらを不活性化するように設計される 血小板、血漿及び赤血球輸血製品の治療特性を保持しながら、有害な白血球として使用できる。同社のINTERCEPT血液システムは、血漿、血小板及び赤血球などの血液成分とともに使用される。   シ―ラスは米国の生物医学的製品企業。血液の安全性を高めるためのシステム「インタ―セプト・ブラッド・システム」を開発。献血血液成分中にある血液媒介病原体を不活性化させる。同システムは欧州、独立国家共同体、中東、その他の国々の血液銀行、病院、大学や政府機関に直接販売される。本社はカリフォルニア州。   
本社所在地 2550 Stanwell Dr. Concord CA 94520 USA
代表者氏名 Daniel N. Swisher ダニエル・N・スウィッシャー
代表者役職名 Independent Chairman of the Board
電話番号 +1 925-288-6000
設立年月日 33482
市場名 NASDAQ National Market System
ipoyear 1997年
従業員数 215人
url www.cerus.com
nasdaq_url https://www.nasdaq.com/symbol/cers
adr_tso
EBITDA EBITDA(百万ドル) -47.46400
終値(lastsale) 6.3
時価総額(marketcap) 843027544.8
時価総額 時価総額(百万ドル) 887.18620
売上高 売上高(百万ドル) 68.18600
企業価値(EV) 企業価値(EV)(百万ドル) 805.11020
当期純利益 当期純利益(百万ドル) -52.07100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cerus Corporation revenues increased 86% to $36.5M. Net loss decreased 24% to $27.2M. Revenues reflect Revenue increase of 75% to $29M Government contracts revenue increase from $3.1M to $7.5M. Lower net loss reflects Foreign exchange loss decrease of 49% to $30K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.34 to -$0.21.

 CERSのテクニカル分析


 CERSのニュース

   Cerus Corporation to Participate in Jefferies Virtual Global Plasma Summit  2021/03/03 13:30:00 Business Wire
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to participate in the Jefferies Virtual Global Plasma Summit on Thursday, March 11, 2021 at 11:00 am PT/ 2:00 pm ET. A live webcast of the events will be available on the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for
   Cerus Corporation Announces Record Fourth Quarter and Full Year 2020 Financial Results  2021/02/25 21:01:00 Business Wire
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and year ended December 31, 2020. Recent developments and highlights include: Record total fourth quarter and full year 2020 revenues of $33.6 million and $114.2 million, respectively. Total revenue was composed of (in millions, except %): Revenue by Segment Three Months Ended Twelve Months Ended December 31, December 31, 2020 2019 Change 2020
   Cerus Corporation and Shandong Zhongbaokang Medical Implements Partner to Establish Joint Venture in China  2021/02/24 22:00:00 Business Wire
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) and Shandong Zhongbaokang Medical Implements Co. Ltd. (ZBK) today announced that they are forming a joint venture (JV) with the intent to develop, obtain regulatory approval for, manufacture and commercialize the INTERCEPT Blood System for platelets and red blood cells in China. The JV, which will be named “Cerus ZBK Biomedical” (CEZB), will be headquartered in Zibo, Shandong Province in eastern China. “We are honored to join fo
   Cerus Corporation to Release Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021  2021/02/11 13:30:00 Business Wire
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full year 2020 financial results will be released on Thursday, February 25, 2021, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides,
   Cerus Corporation to Participate in Upcoming Virtual Investor Conferences  2021/02/04 13:30:00 Business Wire
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to participate in two conferences: BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 17th at 1:30 P.M. ET. The Cowen 41st Annual Health Care Conference on Monday, March 1st at 2:40 P.M. ET. A live webcast of the event
   Cerus Corporation Announces Preliminary Fourth Quarter and Full Year 2020 Product Revenue  2021/01/11 13:30:00 Business Wire
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today preliminary product revenue for the fourth quarter and full year 2020 and provided 2021 product revenue guidance. Cerus’ unaudited preliminary product revenue for the fourth quarter of 2020 totaled $28.2 million, an increase of 35% over the $20.9 million recognized during the same period in the prior year. Based on its fourth quarter unaudited preliminary product revenue, the Company expects full year 2020 produc
   Vivek K. Jayaraman Sells 56,105 Shares of Cerus Co. (NASDAQ:CERS) Stock  2020/12/31 10:28:41 Watchlist News
Cerus Co. (NASDAQ:CERS) COO Vivek K. Jayaraman sold 56,105 shares of the stock in a transaction dated Tuesday, December 22nd. The stock was sold at an average price of $8.00, for a total value of $448,840.00. Following the transaction, the chief operating officer now owns 188,440 shares of the company’s stock, valued at approximately $1,507,520. […]
   Cerus Co. (NASDAQ:CERS) Director Gail Schulze Sells 62,393 Shares  2020/12/16 09:12:42 Watchlist News
Cerus Co. (NASDAQ:CERS) Director Gail Schulze sold 62,393 shares of the business’s stock in a transaction dated Monday, December 14th. The stock was sold at an average price of $7.32, for a total value of $456,716.76. Following the sale, the director now owns 62,393 shares of the company’s stock, valued at approximately $456,716.76. The sale […]
   Cerus’ Distribution Partner, CEI, Announces Three-Year Tender Award with the Minas Gerais Hematology and Hemotherapy Center Foundation (HemoMinas) in Brazil for the INTERCEPT Blood System for Platelets  2020/12/15 13:30:00 Business Wire
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that its distribution partner, Companhia Energética Integrada (CEI), was awarded a three-year contract with the HemoMinas Foundation (“HemoMinas”) of Brazil for the INTERCEPT Blood System for platelets. HemoMinas provides services and blood products in the state of Minas Gerais, and the Hemocentro of Belo Horizonte – the largest blood service of HemoMinas – distributes approximately 25,000 platelet doses to hospi
   Apheresis Equipment Market 2020-2026 Moving Towards Brighter Future | Major Giants – Braun Melsungen AG, Cerus Corporation, Fresenius Medical Care  2020/12/14 15:57:14 OpenPR
In Apheresis Equipment Market report, a systematic investment analysis has been performed which forecasts impending opportunities for the market players. The statistical and numerical data that has been included in this market report is represented with the tables, graphs and
   Cerus Co. (NASDAQ:CERS) Director Gail Schulze Sells 62,393 Shares  2020/12/16 09:12:42 Watchlist News
Cerus Co. (NASDAQ:CERS) Director Gail Schulze sold 62,393 shares of the business’s stock in a transaction dated Monday, December 14th. The stock was sold at an average price of $7.32, for a total value of $456,716.76. Following the sale, the director now owns 62,393 shares of the company’s stock, valued at approximately $456,716.76. The sale […]
   Cerus’ Distribution Partner, CEI, Announces Three-Year Tender Award with the Minas Gerais Hematology and Hemotherapy Center Foundation (HemoMinas) in Brazil for the INTERCEPT Blood System for Platelets  2020/12/15 13:30:00 Business Wire
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that its distribution partner, Companhia Energética Integrada (CEI), was awarded a three-year contract with the HemoMinas Foundation (“HemoMinas”) of Brazil for the INTERCEPT Blood System for platelets. HemoMinas provides services and blood products in the state of Minas Gerais, and the Hemocentro of Belo Horizonte – the largest blood service of HemoMinas – distributes approximately 25,000 platelet doses to hospi
   Apheresis Equipment Market 2020-2026 Moving Towards Brighter Future | Major Giants – Braun Melsungen AG, Cerus Corporation, Fresenius Medical Care  2020/12/14 15:57:14 OpenPR
In Apheresis Equipment Market report, a systematic investment analysis has been performed which forecasts impending opportunities for the market players. The statistical and numerical data that has been included in this market report is represented with the tables, graphs and
   Apheresis Equipment Market 2020-2026 Moving Towards Brighter Future | Major Giants – Braun Melsungen AG, Cerus Corporation, Fresenius Medical Care AG & Co. KGaA, KAWASUMI LABORATORIES  2020/12/10 15:55:56 OpenPR
In Apheresis Equipment Market report, a systematic investment analysis has been performed which forecasts impending opportunities for the market players. The statistical and numerical data that has been included in this market report is represented with the tables, graphs and
   Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting  2020/12/05 00:00:00 Business Wire
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced the oral presentation of a clinical study: “Efficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute COVID-19: A Case Matched Control Study,” presented by Dr. Nina Khanna of the University Hospital of Basel, Switzerland, at the American Society of Hematology Annual Meeting, on Saturday, December 5, 2020, at 2:45 pm/EST. This presentation reviews data on the efficacy

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 シ―ラス CERS Cerus Corporation)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)